Qiagen N.v. · NYSE:QGEN
Qiagen — BofA Securities 2025 Healthcare Conference
52 slides from Qiagen's conference presentation, May 14, 2025
Slide 1: Committed to solid profitable growth: Investor Introduction
Committed to solid profitable growth Investor Introduction Q2 2025 Presentation Titel
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amend
Slide 3: The value of biology has never been stronger
The value of biology has never been stronger Crucial to Improving Direct impact advancing healthcare on your science for all lives Investor Introduction Presentation Titel 3
Slide 4: QIAGEN solutions are used worldwide by researchers
QIAGEN solutions are used worldwide by researchers - from young scientists to Nobel laureates - and clinical labs Investor Introduction Presentation Titel 4
Slide 5: QIAGEN more focused and stronger than ever
QIAGEN more focused and Growth and value stronger than ever ~4-6% CAGR ~$13-14 bn ~$11 bn addressable Life Molecular addressable market QIAGEN (2028) Sciences Diagnostics market customers (2024) ~50% ~50% QIAGEN product Sample technologies Balanced global presence 2024 net sales (%) groups 52 33 15
Slide 6: Leading from the first step in lab workflows
Leading from the first step in lab workflows Samples Sample preparation Detection Insights PCR QIAcuity dPCR #2 Any Genomics / NGS Sample #1 biological technologies QIAGEN Digital Insights #1 sample Diagnostic solutions QuantiFERON #1 QIAstat-Dx #3 Life Sciences Customers Molecular Diagnostics Custo
Slide 7: Strategy: Committed to solid profitable growth
Strategy: Committed to solid profitable growth Our 2028 targets Sharpen focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 ~7% At least 250 bps Net sales CER CAGR Drive efficiency and digitization to fuel (2024-28) growth investments and profitabil
Slide 8: Focusing on attractive opportunities in molecular testing
Focusing on attractive opportunities in molecular testing Product PCR / Nucleic acid Sample technologies Diagnostic solutions NGS / Genomics groups amplification 2024 sales $642 mn $749 mn $300 mn $234 mn Accelerate investments for growth Build on proven leadership QIAcuity #2 QIAstat-Dx #3 QIAGEN #
Slide 9: QIAcuity dPCR
QIAcuity dPCR Quantitative PCR QIAcuity dPCR Next-generation (qPCR) Enabling novel applications sequencing (NGS) e.g., Cell and Gene Therapy e.g., liquid biopsy Lower sensitivity High sensitivity and precision In-depth insights and precision More accurate than qPCR and high precision dPCR – Capturin
Slide 10: Targeting research to clinical healthcare
Targeting research to clinical healthcare Key achievements Scalable systems Low- to high- throughput capabilities QIAcuity One QIAcuity Four QIAcuity Eight >2,700 cumulative placements since launch Academia Overcoming entry barrier vs. qPCR Translational and Ease of use Fully integrated cancer resea
Slide 11: Significant investments into QIAcuity dPCR
Significant investments into QIAcuity dPCR ≥$250 mn QIAcuity net sales CER target (2028) Target Extend Accelerate commercialization new applications into clinical use >3x increase Add >100 assays QIAcuity-Dx of sales specialists for market menu expansion for CGT and enabling MRD and monitoring penet
Slide 12: QIAstat-Dx
QIAstat-Dx Use case: 3-year-old with severe but unspecific GI symptoms Traditional testing Syndromic testing Slow diagnosis and treatment Fast diagnosis enabling better decisions can lead to complexities treatment decisions Identifying unknown diseases at speed Day 1 Day 1 One test within and ease o
Slide 13: QIAstat-Dx offers differentiated features
QIAstat-Dx offers differentiated features Key achievements Strong product capabilities Key differentiators Specification QIAstat-Dx Competition Workflow Additional >4,600 cumulative placements efficiency pathogens since launch Hands-on time ~1 min >5 min and safety on panels for for broader qPCR rob
Slide 14: Expanding global presence and differentiated menu
Expanding global presence and differentiated menu ≥$200 mn QIAstat-Dx net sales CER target (2028) Grow installed Small hospitals Medium hospitals Large hospital networks customer Public health labs Regional reference labs National reference labs base Submitted to FDA Low-throughput High-throughput c
Slide 15: QIAGEN Digital Insights unlocking the power of genomics
QIAGEN Digital QIAGEN unlocking the power of genomics Insights Development Genomic data In 2003, the first Today, any human human genome took genome can be read in 13 years 5 hours Sequencing Powerful analytics costs $100 / to understand >$1 bn / genome sequencing run 2000 2010 2020 2030 genomics Th
Slide 16: Top bioinformatics for research to clinical customers
Top bioinformatics for research to clinical customers Key achievements Addressing large customer base Delivering QDI software solutions for NGS workflow #1 Research – in bioinformatics software for research and clinical Scientific discovery Pharma / Biotech 6 Academia Sample prep Library prep NGS an
Slide 17: Case study: Research Advancing drug development
Case study: Research Advancing drug development Pharma challenge QDI pivotal to drug discovery Over 50,000 scientific publications cite our software Key to understanding disease pathways, targets and measure changes 24 of the Top 25 Pharma companies use QDI Significant number of failures without the
Slide 18: Case study: Clinical Enhancing patient outcomes
Case study: Clinical Enhancing patient outcomes Patient situation QDI-enhanced patient outcome Mutation identification and recommendation by QDI Profile Male (early 70s) Targeted therapy leading to life-saving disease remission Diagnosis QIAGEN Clinical Leukemia linked to rare gene mutation Insights
Slide 19: Focus on SaaS subscription model and AI to expand market leadership
Focus on "SaaS" subscription model and AI to expand market leadership 2028 goals Coming in 2025 Deepen global commercial reach and +40% 3 new AI product SaaS transition for sustainable growth SaaS sales specialists enhancements >14 10+ new DATA Invest in new AI technologies AI-enabled applications S
Slide 20: Investing to extend market leadership
Investing to extend market leadership ≥$200 mn QDI net sales CER target (2028) Extend leadership in curated Deepen global Invest in new AI and other knowledge commercial reach technologies Expand QIAGEN knowledge base into Adopt SaaS go-to-market Continue advancing software spatial, proteomics and m
Slide 21: Sample technologies
Sample technologies Laboratory workflow Differentiated solutions for PCR Valuable Biological Sample modular, integrated workflows molecular sample technologies insights Fast time to result, scalability Critical step in and ease of use dPCR High-quality molecular sample prep key to workflows Platform
Slide 22: Leader in the first step of lab workflows
Leader in the first step of lab workflows Key achievements Comprehensive Any >350 DNA / RNA consumables portfolio biological sample different sample kits target analytes >120 mn QIAGEN preparations e.g., tissue, cells, blood, for manual and sold per year including variations serum, wastewater automa
Slide 23: On the offense expanding our top automation portfolio
On the offense expanding our top automation portfolio Low-throughput Mid-throughput High-throughput ≥$750 mn Sample technologies net sales CER target (2028) QIAmini QIAsymphony QIAsprint Connect Connect Launch 2026 Launch 2025 Launch 2026 Addition to QIAcube / EZ Flagship system upgrade, Market Entr
Slide 24: QuantiFERON Tuberculosis: A highly contagious and lethal bacterial infection
QuantiFERON Tuberculosis: A highly contagious and lethal bacterial infection 1 in 4 Broad health risk Global relevance people have a latent TB bacterial infection 1 in 10 EMEA of these people will develop an Immunocompromised ~10 mn active TB bacterial infection patients North America Japan >75 mn A
Slide 25: Best-positioned test for latent TB detection
Best-positioned test for latent TB detection QuantiFERON Tuberculin Key achievements Advantages over Specification blood test skin test skin test $454 mn Customizable automated workflow High accuracy and specificity 2024 net sales (+89% vs. 2019) Only one patient visit Electronic results >125 mn Qua
Slide 26: Driving skin test conversion with unrivaled automation
Driving skin test conversion with unrivaled automation ≥$600 mn QuantiFERON Leading automation advantage net sales CER target (2028) Automated Automated Increase liquid handling assay and result Partnership with customer base Diasorin to expand into Lyme disease (EU and U.S.) Large potential in skin
Slide 27: Initiatives to fuel growth investments and achieve ≥31% margin
Initiatives to fuel growth investments and achieve ≥31% adjusted operating income margin in 2028 Operational excellence Digitization Positioning QIAGEN for stronger profitable growth Accelerating growth and efficiency across QIAGEN Organizational design Portfolio streamlining >6 million ~30 website
Slide 28: Executing our strategy with empowered QIAGENers
Executing our strategy with empowered QIAGENers Great Great Great Great Great Great ~5,700 Place Place Place Place Place Place To To To To To To Work ® Work ® Work ® Work ® Work ® Work ® Certified Certificada Certificada Certified Certified Certified QIAGENers NOV 2023–NOV 2024 DEC 2022–DEC 2023 OCT
Slide 29: Embracing ESG for all stakeholders
Embracing ESG for all stakeholders Net zero Top ESG ratings Environmental responsibility carbon emission target (2050) Investing in people 37% female leadership (2024) Serving society >50 public health partnerships (2024) Business with integrity ~8,000 compliance trainings completed (2024) Investor
Slide 30: Leveraging strong balance sheet and cash flows to enhance growth
Leveraging strong balance sheet and cash flows to enhance growth Profitable targeted investments Annual dividend NEW Organic initiation investments Into growth pillars and digitization to fuel profitable business expansion Seeking shareholder approval for dividend at the upcoming AGM in June 2025 Fo
Slide 31: Reinvigorated leadership team dedicated to deliver
Reinvigorated leadership team dedicated to deliver Supervisory Board Executive Committee Lawrence A. Rosen Metin Colpan Chair Co-founder of QIAGEN Thierry Bernard Roland Sackers Joined in 2013 Chief Executive Officer Chief Financial Officer Joined EC in 2015 Joined EC in 2004 Toralf Haag Ross Levine
Slide 32: Q1 2025 results
Q1 2025 results Solid results exceeding outlook May 7, 2025
Slide 33: On track to achieve 2025 targets
On track to achieve 2025 targets Delivering solid financial performance Net sales and adjusted EPS exceeded outlook with higher profitability Driving growth through portfolio expansion Continuing momentum across growth pillars with important contributions to serve customers in both Life Sciences and
Slide 34: Q1 2025: Solid results exceeding outlook
Q1 2025: Solid results exceeding outlook Growth Solid start to 2025 with broad-based growth across the portfolio $483 mn ($491 mn CER) • Net sales +7% CER to $483 mn above outlook of ~+3% Net sales • QuantiFERON +16% CER, QIAstat-Dx +37% CER; QIAcuity and QDI delivered +7% CER high-single-digit grow
Slide 35: Q1 2025: Sales performance and key developments
Q1 2025: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) +7% Sample • 1% CER sales decline reflecting lower demand for manual kits CER(1) technologies • Weaker instrument trends amid cautious customer spending 483 459 Sample • +16% CER g
Slide 36: Q1 2025: Portfolio developments
Q1 2025: Portfolio developments Sample technologies: QIAstat-Dx: QIAGEN Digital Insights: Supporting global health priorities Expanding syndromic testing in the U.S. Boosting local bioinformatics capacity New malaria testing solution launched Second GI mini panel cleared in the U.S. New data center
Slide 37: Q1 2025: Significant improvement in adjusted operating profitability
Q1 2025: Significant improvement in adjusted operating profitability Adj. operating income margin Adj. EPS ahead of Q1 2025 outlook Adj. +22% to $144 million on efficiency operating gains and NeuMoDx discontinuation +4.1 ppt 29.8% income 25.7% Non- Lower than expected adjusted tax rate operating (20
Slide 38: Q1 2025: Enhancing operating cash flow generation
Q1 2025: Enhancing operating cash flow generation Using healthy cash flows and strong balance sheet to re-invest in growth and drive shareholder returns Cash flow(1) Debt maturity overview(3) (in $ millions) 615 115 500 In $ millions Q1 2025 Q1 2024 Change Likely Operating cash flow 140 133 +5% repa
Slide 39: Outlook: Q2 and FY 2025
Outlook: Q2 and FY 2025 As of May 7, 2025 Outlook Q2 2025 FY 2025 Net sales ≥+5% CER / ~+4% CER / ≥+5% CER core portfolio(1) ~+5% CER core portfolio(1) Anticipated currency impact Positive impact of ~+1ppt Neutral FX impact Adjusted diluted EPS ≥$0.60 CER ~$2.35 CER Anticipated currency impact Neutr
Slide 40: Transition in QIAGEN Supervisory Board leadership
Transition in QIAGEN Supervisory Board leadership Stephen H. Rusckowski QIAGEN Supervisory Board members – To be elected Chairman of Supervisory Board(1) Returning to eight members as planned in 2024 • Joined Supervisory Board in 2023 • Currently Chair of Nomination & Governance Committee and member
Slide 41: Appendix
QIAGEN Appendix
Slide 42: Q2 and FY 2025: Outlook and assumptions
Q2 and FY 2025: Outlook and assumptions (As of May 7, 2025) Q2 2025 outlook FY 2025 outlook Net sales ≥+5% CER / ≥+5% CER core portfolio(1) ~+4% CER / ~+5% CER core portfolio(1) Anticipated currency impact(2) Positive impact of ~+1 ppt Neutral FX impact Adjusted diluted EPS(3) ≥$0.60 CER ~$2.35 CER
Slide 43: Q1 2025: Consolidated Statements of Income (unaudited)
Q1 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended March 31, 2025 March 31, 2024 Net sales 483,456 458,796 Cost of sales: Cost of sales 161,294 151,734 Acquisition-related intangible amortization 13,481 16,073 Total cost o
Slide 44: 2025: Quarterly sales by product group
2025: Quarterly sales by product group Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 150 -3% -1% Diagnostic solutions(1) 187 9% 11% Of which QuantiFE
Slide 45: Q1 2025: Reconciliation to adjusted results (unaudited)
Q1 2025: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* First quarter 2025 Reported results 483.5 308.7 115.3 119.5 (28.7) 24 % 90.8 0.41 Adjustments Business integration, a
Slide 46: Q1 2025: Footnotes for reconciliation to adjusted results
Q1 2025: Footnotes for reconciliation to adjusted results (unaudited) a. Includes costs incurred in connection with streamlining operations and improving overall efficiency as well as costs related to various contemplated and completed acquisition projects and their subsequent integration. b. Adjust
Slide 47: 2025: Quarterly income statement summary
2025: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Net sales 483.5 Net sales (CER) 491.2 Gross profit 308.7 Gross profit margin 63.8% Adjusted gross profit 325.9 Adjusted gross profit margin 67.4% Operating
Slide 48: Consolidated Balance Sheets
Consolidated Balance Sheets March 31, December 31, March 31, December 31, (In $ thousands, except par value) 2025 2024 (In $ thousands, except par value) 2025 2024 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 638,756 663,555 Current portion of long-term debt 55,693
Slide 49: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Three months ended March 31, March 31, Three months ended March 31, March 31, (In $ thousands) 2025 2024 (In $ thousands) 2025 2024 Cash flows from operating activities: Cash flows from financing activities: Net income 90,758 80,673 Capital repayment
Slide 50: Q1 2025: Currency impact
Q1 2025: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q1 2025 U.S. dollar 272.4 272.5 55% 0.1 Euro 97.7 100.6 21% 2.9 British pound 15.0 15.2 3% 0.2 Japanese yen 11.5 11.8 2% 0.3 Other currencies 87.0 91.1 19% 4.2 Tot
Slide 51: Employees as of March 31, 2025
Employees as of March 31, 2025 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q1 2025 Q4 2024 Change Production 340 1,245 143 1,728 1,636 6% R&D 165 627 55 847 1,001 -15% Sales 547 835 719 2,101 2,147 -2% Marketing 66 185 76 327 324 1% Administration 81 432 157 670 657
Slide 52: Your contacts
Your contacts Dr. Domenica Martorana Calendar Associate Director Global Investor Relations Annual General Meeting June 2025 Phone: +49 2103 29 11244 Q2 2025 results August 2025 E-mail: domenica.martorana@qiagen.com Q3 2025 results November 2025 Alexandra Koenig Coordinator Share information Investor